On the move all over the world.
For surgeons and patients.
As an innovation leader, Medartis promotes technologies and solutions for osteosynthesis in the fields of cranio-maxillofacial surgery as well as upper and lower extremities. In close cooperation with international surgeons and scientists from leading clinics and universities. Developed and produced at the headquarters in Basel/Switzerland. For optimized treatment and an improved quality of life for patients. Worldwide.
million CHF net sales in 2021160
« Medartis stands for Swiss engineered, high-tech innovation that addresses unmet clinical needs. We are passionate about developing advanced implant solutions for medical professionals with the aim of improving patient’s treatment and restore their quality of life. »
Chief Executive Officer
Member of the Executive Management Board
With the foundation of Medartis in 1997, Dr. h.c. Thomas Straumann laid the cornerstone for our current strong position in implants for cranio-maxillofacial surgery and the extremities. That was just the beginning. Because we're moving on. And making history in osteosynthesis.
Prof. Dr. Reinhard Straumann founded the Institut Straumann AG which specialzed in metallurgy for the watchmaking industry.
Merger of metallurgy and medicine by Dr. h.c. Fritz Straumann.
When Thomas father, Fritz Straumann, died in 1988, Thomas Straumann and his siblings faced a huge decision: What should they do with the company they were about to inherit? Thomas Straumann knew he wanted to build something of his own, and he was particularly interested in the dental sector.
So in 1990 the largest segment, orthopaedic implants, marketed under the "Synthes" brand, was sold to Rudolf Maag, who headed this business unit. The new company was given the name Stratec Medical and from then on wrote its own success story.
Foundation of Medartis AG with headquarters in Basel/Switzerland by Dr. h.c. Thomas Straumann. Acquisition of a small, independent specialist for oral and maxillofacial surgery and further development of the portfolio.
Initially still distributed via the dental sister-company Straumann Holding AG, Medartis is now selling its implants directly. It is founding a subsidiary in Umkirch, then in Vienna, in Lyon, in Batley, in Philadelphia. Over the years branches follow all over the world.
TriLock is launched: the first multidirectional, angle-stable locking system of its kind. This technology is the basis of the APTUS implant solution, which Medartis launches in the same year for hand and wrist surgery and later for the lower extremities. In the same year, Straumann and Miesch found the International Bone Research Association (IBRA) with renowned surgeons in Zurich. The first scientific seminar and the first general assembly take place two years later at the Inselspital in Bern.
Medartis starts its own production. A modern production facility for screws and plates is built in the empty halls of the family-owned Tschudin + Heid company in Bretzwil, Basel.
Medartis is launching another technology that sets new standards in the operating theatre.
SpeedTip, probably the sharpest screw in the world. Equally appreciated by surgeons: the HexaDrive screw head design, thanks to which the screw adheres to the screwdriver.
All under one roof: Medartis moves into the anchor tenant in the modern Stücki Business Park in Basel's Basel's working-class district of Kleinhüningen. Today, the Business Park is home numerous life science companies.
Medartis is expanding the range of of its implants into the lower extremities (foot and ankles). In the upper upper extremities, implants for the for the elbow.
Introduction of cannulated compression screws 2.2 and 3.0 in 2011 and soon after the arthrodesis system.
Introduction of the orthognathic system and completion of the elbow system.
CEO Willi Miesch is honoured on several occasions awards for his work at Medartis: He receives the "SME Entrepreneur Award " (2005), the "Prix SVC" (2015) and the prize EY Entrepreneur of the Year" (2016).
Start of the focus on lower extremities with the introduction of new foot and ankle systems.
Acquisition of the Mimedis company, active in pre-operative planning and 3D printing of patient-specific implants.
On 23 March 2018, Medartis is in the spotlight. In a challenging stock market year, Medartis dares to go public and is rewarded. The share price skyrockets, revealing a company market value of around CHF 600 million.
Promoting research and retaining customers - this is also possible during the Corona pandemic. The "Cadaveric Masterclass" at the digital congress of the Federation of European Societies for Surgery of the Hand (FESSH) in June, Medartis will broadcast live. A logistical feat.
The privately owned orthopaedic company Nextremity Solutions Inc. in Warsaw, USA, becomes part of Medartis. The takeover is intended to give the US business a boost, as the preferences of the US surgeons partly differ from those in Europe.
The Executive Management Board of Medartis.
The Board of Directors of Medartis.